Biodesix Inc
$ 15.06
1.76%
12 Jun - close price
- Market Cap 155,958,000 USD
- Current Price $ 15.06
- High / Low $ 15.96 / 14.81
- Stock P/E N/A
- Book Value 0.90
- EPS -3.96
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -3.16 %
- 52 Week High 20.21
- 52 Week Low 5.00
About
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$30.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-26 | 2025-11-03 | 2025-08-07 | 2025-05-13 | 2025-03-03 | 2024-11-01 | 2024-08-07 | 2024-05-08 | 2024-03-01 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.81 | -0.49 | -1.16 | -1.6 | -1.6 | -0.06 | -1.4 | -1.6 | -2.8 | -0.1 | -2.8 | -3.4 |
| Estimated EPS | -1.1 | -0.866 | -1.51 | -1.37 | -1.4 | -0.0667 | -1.52 | -1.84 | -2.87 | -0.11 | -3 | -4.13 |
| Surprise | 0.29 | 0.376 | 0.35 | -0.23 | -0.2 | 0.0067 | 0.12 | 0.24 | 0.07 | 0.01 | 0.2 | 0.73 |
| Surprise Percentage | 26.3636% | 43.418% | 23.1788% | -16.7883% | -14.2857% | 10.045% | 7.8947% | 13.0435% | 2.439% | 9.0909% | 6.6667% | 17.6755% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.88 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDSX
2026-06-11 14:08:47
Biodesix, Inc. (BDSX) reported a narrower-than-expected loss in Q1, exceeding revenue estimates. The company posted a loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.23 loss per share. Revenue for the quarter reached $11.4 million, surpassing the consensus estimate of $9.59 million.
2026-06-01 10:39:48
This article reports on a recent SEC filing for Biodesix Inc. (NASDAQ: BDSX), specifically an EFFECT filing. The filing indicates an effectiveness date of May 29, 2026, for a Form S-3 (Shelf Registration Statement), with a CIK of 0001439725. The company's stock overview, market data, and recent news and filings are also included.
2026-05-30 20:39:48
Biodesix, Inc. (NASDAQ: BDSX) has filed a prospectus to register the resale of up to 375,000 shares of its common stock by the selling stockholder, Perceptive Credit Holdings IV, LP. These shares are issuable upon the exercise of specific warrant certificates, and the registration fulfills contractual obligations. Biodesix will not receive proceeds from the resale of these shares, only if the warrants are exercised for cash.
2026-05-23 12:38:52
Canaccord has increased its price target for Biodesix (BDSX) from $20 to $22, maintaining a Buy rating, due to higher revenue assumptions and improved operating margins in its 10-year DCF model. This adjustment follows Biodesix's strong Q1 2026 results, which showed Diagnostic Testing revenue growth of 37% year-over-year and total revenue up 42% to $25.6 million. The company, which provides blood-based diagnostic services for lung disease, saw increased test volumes and higher average revenue per test driven by expanded payer coverage.
2026-05-23 05:40:31
This article provides a compilation of recent news and analysis related to Biodesix Inc (NASDAQ:BDSX). It includes past earnings reports, analyst expectations for stock rallies, and various other stock-related news where BDSX is mentioned alongside other companies. The current stock price and after-hours performance are also noted.
2026-05-22 03:33:03
Biodesix (NASDAQ: BDSX) has filed an S-3 registration statement to allow Perceptive Credit Holdings IV, LP to resell up to 375,000 shares of common stock. These shares are issuable upon the exercise of warrants granted under multiple amendments to a credit agreement. Biodesix will not receive proceeds from the resale of these shares, but would receive proceeds if the warrants are exercised for cash.
